Business context and reporting period
Basel Medical Group Ltd filed this Form 6-K for October 2026, reporting a registered direct offering priced on October 8, 2026, under agreements entered into on October 7. The filing concerns the financing transaction, not a period of operating results.
Financial and offering details
- The Company agreed to sell 6,000,000 units at US$1.33 per unit, for expected gross proceeds of US$7.98 million and estimated net proceeds of approximately US$7.28 million. The filing does not provide a separate breakdown of commissions and offering expenses.
- Each unit consists of one ordinary share or one pre-funded warrant, plus one common warrant. Net proceeds are intended for working capital, mergers and acquisitions, and other general corporate purposes.
- The filing reports 1,582,111 ordinary shares outstanding before the offering and 7,582,111 immediately upon completion, plus 6,000,000 common warrants. It does not clarify the expected closing date or provide a separate pro forma share count accounting for pre-funded warrants.
- Common warrants are exercisable immediately at 110% of the unit offering price and expire five years after issuance. They may also be exercised on a zero-cash basis; the Company expects no additional proceeds from warrant exercise. Full zero-cash exercise would result in 6,000,000 additional ordinary shares.
- Pre-funded warrants are exercisable for one share at US$0.01 per share, subject to beneficial-ownership limits of 4.99%, adjustable at the holder’s election up to 9.99%.
- The filing provides no revenue, profit, cash flow, margin, debt, or liquidity figures.
Material changes versus the prior comparable period
No comparable-period operating or financial results are provided. The principal disclosed change is the planned issuance of securities that would increase the reported ordinary shares outstanding from 1,582,111 to 7,582,111 upon offering completion, with further potential dilution from warrant exercises.
Outlook, risks, and unusual terms
- The Company has stated intended uses for the proceeds but gives no financial forecast or quantified outlook.
- Zero-cash exercise of common warrants could add up to 6,000,000 shares without generating additional cash for the Company.
- The Company, its executive officers and directors, and certain 5%-or-more shareholders are subject to 180-day lock-ups, with specified exceptions and placement-agent consent provisions. The Company also agreed to restrictions on additional securities issuance and capital-raising transactions during that period.
- The common and pre-funded warrants will not be listed or quoted on an exchange. The ordinary shares and shares issuable under the offering are registered and described as freely tradeable following closing.
Important facts for investors to verify
- Whether and when the offering closed, and the final number of ordinary shares versus pre-funded warrants issued.
- Final net proceeds and actual commissions and offering expenses.
- Fully diluted share count, including pre-funded warrants and any common-warrant exercises, particularly zero-cash exercises.
- Use of proceeds and the Company’s current operating results, cash position, debt, and liquidity, which are not stated in this filing.
- The detailed warrant, purchase, and lock-up terms in the filed exhibits.